72.93MMarket Cap-1.67P/E (TTM)
0.500High0.461Low122.92KVolume0.475Open0.488Pre Close58.45KTurnover0.13%Turnover RatioLossP/E (Static)150.83MShares2.10052wk High-1.78P/B44.67MFloat Cap0.32152wk Low--Dividend TTM92.39MShs Float30.000Historical High--Div YieldTTM8.07%Amplitude0.321Historical Low0.475Avg Price1Lot Size
OptiNose Stock Forum
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
Optinose (NASDAQ:OPTN) announced the peer-reviewed publication of a paper in the International Forum of Allergy & Rhinology, highlighting the benefits of XHANCE in chronic rhinosinusitis (CRS) patients. The study, based on two 24-week randomized trials (ReOpen1 and ReOpen2), evaluated XHANCE versus EDS-placebo in CRS patients with and without prio...
OptiNose Q1 EPS USD -0.12 Vs. Ibes Estimate USD -0.11
Optinose Sees 2024 XHANCE Revenue in $85M to $95M Range >OPTN
NEWS
Optinose Announces $55 Million Registered Direct Offering
loading...
loading...
📊⚡️📊
Polyps
$BeiGene (BGNE.US)$ : Approved 3/8 🎉
⇒ BRUKINSA + obinutuzumab
⇒ Follicular Lymphoma
⇒ sNDA
⇒ PDUFA date: Mar 2024
$Bristol-Myers Squibb (BMY.US)$ : Approved 3/8 🎉
⇒ Opdivo ® + Cisplatin & Gemcitabine
⇒ Urothelial carcinoma
⇒ sBLA
⇒ PDUFA: 04/05/24
$Vanda Pharmaceuticals (VNDA.US)$ : CRL 3/4 🙁
⇒ HETLIOZ®
⇒ insomnia
⇒ sNDA
⇒ PDUFA: 03/04/24
$Eyenovia (EYEN.US)$ : Approved 3/4 🎉
⇒ Clobetasol propionate ophthalmic susp. 0.05% (APP13007)
⇒ postop eye pa...
No comment yet